International Journal of Clinical Case Reports, 2025, Vol.15, No.4, 159-170 http://medscipublisher.com/index.php/ijccr 168 Kirchberger I., Meisinger C., Heier M., Zimmermann A., Thorand B., Autenrieth C., Peters A., Ladwig K., and Döring A., 2012, Patterns of multimorbidity in the aged population, results from the KORA-Age study, PLoS One, 7: e30556. Kristensen R., Nørgaard A., Jensen-Dahm C., Gasse C., Wimberley T., and Waldemar G., 2018, Polypharmacy and potentially inappropriate medication in people with dementia: a nationwide study, Journal of Alzheimer's Disease, 63: 383-394. https://doi.org/10.3233/JAD-170905 Kurczewska-Michalak M., Lewek P., Jankowska-Polańska B., Giardini A., Granata N., Maffoni M., Costa E., Midão L., and Kardas P., 2021, Polypharmacy management in the older adults: a scoping review of available interventions, Frontiers in Pharmacology, 12: 734045. https://doi.org/10.3389/fphar.2021.734045 Leelakanok N., Holcombe A., Lund B., Gu X., and Schweizer M., 2017, Association between polypharmacy and death: a systematic review and meta-analysis, Journal of the American Pharmacists Association, 57(6): 729-738. https://doi.org/10.1016/j.japh.2017.06.002 López-Rodríguez J., Rogero-Blanco E., Aza-Pascual-Salcedo M., López-Verde F., Pico-Soler V., Leiva-Fernández F., Prados-Torres J., Prados-Torres A., and Cura-González I., 2020, Potentially inappropriate prescriptions according to explicit and implicit criteria in patients with multimorbidity and polypharmacy, MULTIPAP: a cross-sectional study, PLoS One, 15(8): e0237186. https://doi.org/10.1371/journal.pone.0237186 Lu J., Wang Y., Hou L., Zuo Z., Zhang N., and Wei A., 2021, Multimorbidity patterns in old adults and their associated multi-layered factors: a cross-sectional study, BMC Geriatrics, 21(1): 372. https://doi.org/10.1186/s12877-021-02292-w Lv J., Li R., Yuan L., Yang X., Wang Y., Ye Z., and Huang F., 2022, Research on the frailty status and adverse outcomes of elderly patients with multimorbidity, BMC Geriatrics, 22(1): 560. https://doi.org/10.1186/s12877-022-03194-1 Maher R., Hanlon J., and Hajjar E., 2014, Clinical consequences of polypharmacy in elderly, Expert Opinion on Drug Safety, 13: 57-65. https://doi.org/10.1517/14740338.2013.827660 Mair A., Antoniadou E., Hendry A., and Gabrovec B., 2020, Appropriate polypharmacy: a barometer for integrated care, Journal of Integrated Care, 29(2): 204-214. https://doi.org/10.1108/jica-04-2020-0019 Mangin D., Bahat G., Golomb B., Mallery L., Moorhouse P., Onder G., Petrovic M., and Garfinkel D., 2018, International group for reducing inappropriate medication use and polypharmacy (IGRIMUP): position statement and 10 recommendations for action, Drugs and Aging, 35: 575-587. https://doi.org/10.1007/s40266-018-0554-2 Marengoni A., Roso-Llorach A., Vetrano D., Fernández S., Guisado-Clavero M., Violán C., and Calderón-Larrañaga A., 2019, Patterns of multimorbidity in a population-based cohort of older people: sociodemographic, lifestyle, and functional differences, The Journals of Gerontology, Series A, Biological Sciences and Medical Sciences, 75(4): 798-805. https://doi.org/10.1093/gerona/glz137 Masnoon N., Shakib S., Kalisch-Ellett L., and Caughey G., 2017, What is polypharmacy? a systematic review of definitions, BMC Geriatrics, 17(1): 230. https://doi.org/10.1186/s12877-017-0621-2 McIntosh J., Alonso A., Maclure K., Stewart D., Kempen T., Mair A., Castel-Branco M., Codina C., Fernandez-Llimos F., Fleming G., Gennimata D., Gillespie U., Harrison C., Illario M., Junius-Walker U., Kampolis C., Kardas P., Lewek P., Malva J., Menditto E., Scullin C., and Wiese B., 2018, A case study of polypharmacy management in nine European countries: Implications for change management and implementation, PLoS ONE, 13(4): e0195232. https://doi.org/10.1371/journal.pone.0195232 Mehta R., Kochar B., Kennelty K., Ernst M., and Chan A., 2021, Emerging approaches to polypharmacy among older adults, Nature Aging, 1: 347-356. https://doi.org/10.1038/s43587-021-00045-3 Mohamed M., Mohile S., Juba K., Awad H., Wells M., Loh K., Flannery M., Culakova E., Tylock R., and Ramsdale E., 2023, Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer, Cancer, 129: 1096-1104. https://doi.org/10.1002/cncr.34642 Molokhia M., and Majeed A., 2017, Current and future perspectives on the management of polypharmacy, BMC Family Practice, 18(1): 70. https://doi.org/10.1186/s12875-017-0642-0 Mueller C., Molokhia M., Perera G., Veronese N., Stubbs B., Shetty H., Codling D., Huntley J., and Stewart R., 2018, Polypharmacy in people with dementia: associations with adverse health outcomes, Experimental Gerontology, 106: 240-245. https://doi.org/10.1016/j.exger.2018.02.011 Muth C., Blom J., Smith S., Johnell K., González-González A., Nguyen T., Brueckle M., Cesari M., Tinetti M., and Valderas J., 2018, Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus, Journal of Internal Medicine, 285: 272-288. https://doi.org/10.1111/joim.12842 Nicholson K., Liu W., Fitzpatrick D., Hardacre K., Roberts S., Salerno J., Stranges S., Fortin M., and Mangin D., 2024, Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review, The Lancet, Healthy Longevity, 5(4): e287-296. https://doi.org/10.1016/s2666-7568(24)00007-2
RkJQdWJsaXNoZXIy MjQ4ODYzNA==